Partidos, Charalambos D.
Takeda Vaccines Inc.,
United States
2025 Rank: 149005
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 1224 out of 75944 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 149005 | 148303 |
| Total Cites | 5342 | 6056 |
| H-index | 32 | 34 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 109 | 119 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 848 | 1033 |
| Number of Single+First+Last Authored Papers | 54 | 54 |
| Total Cites to Single+First+Last Authored Papers | 1499 | 1780 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4305 | 4650 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.30 |
| Self-Citation Percentage |
11.79%
|
|
Partidos, Charalambos D.
Takeda Vaccines Inc.,
United States
2024 Rank: 138857
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 1169 out of 71672 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 138857 | 138195 |
| Total Cites | 5172 | 5876 |
| H-index | 32 | 34 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 108 | 118 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 836 | 1018 |
| Number of Single+First+Last Authored Papers | 54 | 54 |
| Total Cites to Single+First+Last Authored Papers | 1467 | 1744 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4157 | 4497 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.31 |
| Self-Citation Percentage |
11.98%
|
|
Partidos, Charalambos D.
Takeda Vaccines Inc.,
United States
2023 Rank: 133467
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 1148 out of 68279 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 133467 | 129737 |
| Total Cites | 4997 | 5688 |
| H-index | 30 | 34 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 104 | 114 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 820 | 1001 |
| Number of Single+First+Last Authored Papers | 54 | 54 |
| Total Cites to Single+First+Last Authored Papers | 1444 | 1719 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4007 | 4337 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.31 |
| Self-Citation Percentage |
12.15%
|
|
Partidos, Charalambos D.
Takeda Vaccines Inc.,
United States
2022 Rank: 127779
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 1132 out of 65731 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 127779 | 123347 |
| Total Cites | 4732 | 5410 |
| H-index | 30 | 33 |
| Hm-index | 15 | 17 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 100 | 110 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 798 | 978 |
| Number of Single+First+Last Authored Papers | 54 | 54 |
| Total Cites to Single+First+Last Authored Papers | 1394 | 1667 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3796 | 4119 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.31 |
| Self-Citation Percentage |
12.53%
|
|
Partidos, Charalambos D.
Takeda Vaccines,
United States
2021 Rank: 124615
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 1114 out of 64670 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 124615 | 117848 |
| Total Cites | 4571 | 5243 |
| H-index | 29 | 33 |
| Hm-index | 15 | 17 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 98 | 108 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 782 | 961 |
| Number of Single+First+Last Authored Papers | 54 | 54 |
| Total Cites to Single+First+Last Authored Papers | 1366 | 1638 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3664 | 3982 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.32 |
| Self-Citation Percentage |
12.82%
|
|
Partidos, Charalambos D.
Takeda Vaccines, Inc.,
United States
2020 Rank: 115286
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Virology
SubField 2:
Immunology
Rank in SubField 1: 1131 out of 58416 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 115286 | 109846 |
| Total Cites | 4306 | 4960 |
| H-index | 29 | 32 |
| Hm-index | 15 | 17 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 92 | 102 |
| Number of Single+First Authored Papers | 36 | 36 |
| Total Cites to Single+First Authored Papers | 752 | 929 |
| Number of Single+First+Last Authored Papers | 54 | 54 |
| Total Cites to Single+First+Last Authored Papers | 1310 | 1579 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3435 | 3739 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.33 |
| Self-Citation Percentage |
13.19%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.